electroCore, Inc. to Report Third Quarter Financial Results on November 13, 2018
30 Outubro 2018 - 5:05PM
electroCore, Inc. (“electroCore”) (Nasdaq: ECOR), a
commercial-stage bioelectronic medicine company, today announced
that it will release financial results for the third quarter ended
September 30, 2018 after the close of trading on Tuesday, November
13, 2018. The company’s management team will host a
corresponding conference call beginning at 4:30 PM ET.
Investors interested in listening to the conference call may do
so by dialing (877) 371-5740 for domestic callers or (629) 228-0724
for international callers, using Conference ID: 5067968. A live
webcast of the event will be available on the “Investors” section
of the company’s website at: www.electrocore.com. The webcast will
be archived for 30 days.
About electroCore, Inc.
electroCore, Inc. is a commercial-stage bioelectronic medicine
company dedicated to improving patient outcomes through its
platform non-invasive vagus nerve stimulation therapy initially
focused on the treatment of multiple conditions in neurology and
rheumatology. The company’s initial targets are the acute treatment
of migraine and episodic cluster headache.
Forward-Looking Statements
This press release may contain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such forward-looking statements include, but are not limited
to, statements about electroCore's business prospects and product
development plans, its pipeline or potential markets for its
technologies, and other statements that are not historical in
nature, particularly those that utilize terminology such as
"anticipates," "will," "expects," "believes," "intends,"
other words of similar meaning, derivations of such words and the
use of future dates. Actual results could differ from those
projected in any forward-looking statements due to numerous
factors. Such factors include, among others, the ability to raise
the additional funding needed to continue to pursue electroCore’s
business and product development plans, the inherent uncertainties
associated with developing new products or technologies, the
ability to commercialize gammaCore™, competition in the industry in
which electroCore operates and overall market conditions. Any
forward-looking statements are made as of the date of this press
release, and electroCore assumes no obligation to update the
forward-looking statements or to update the reasons why actual
results could differ from those projected in the forward-looking
statements, except as required by law. Investors should
consult all of the information set forth herein and should also
refer to the risk factor disclosure set forth in the reports and
other documents electroCore files with the SEC available at
www.sec.gov.
Contacts
Investors:Greg Chodaczek or Lynn LewisGilmartin
Groupinvestors@electrocore.com(646) 924-1769
or
Media:Alexandra Canale GCI Health(617)
921-9353alexandra.canale@gcihealth.com
electroCore (NASDAQ:ECOR)
Gráfico Histórico do Ativo
De Set 2024 até Out 2024
electroCore (NASDAQ:ECOR)
Gráfico Histórico do Ativo
De Out 2023 até Out 2024